Why Dr. Scarlett and Co. are smiling

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Why Dr. Scarlett and Co. are smiling

Post by biopearl123 » Sun Nov 13, 2022 9:24 pm

Take a look at the current abstracts submitted to ASH. Specifically look at what we know so far beyond TI, duration of drug effect, depth of response etc. Take a look at over all survival and progression free survival. Here is Geron’s criterion for PFS in IMerge:

“ Progression Free Survival (PFS) [ Time Frame: During study (approximately 2 years) ]
Progression free survival will be assessed as the time interval from study Day 1 to the first date of disease progression or death from any cause, whichever occurs first. As per IWG criteria disease progression is defined as: at least one of the following: at least 50 percent (%) decrement from maximum response levels in granulocytes or platelets; reduction in hemoglobin by greater than or equal to (>=) 1.5 gram per deciliter (g/dL); transfusion dependence.”

Here is the definition for PFS presented in Dr. Santini’s abstract on Luspatercept:

“PFS was defined as the time from MDS diagnosis to acute myeloid leukemia progression.”

Pretty different to my eye. Now go read the abstracts for both the Medalist and the IMerge studies that are being presented. Again, while we don’t have the COMMANDS data yet, the PFS and OS Luspatercept data to date does not look overwhelming. (Progressive disease seems to be driving by genetic signature and very low risk disease rarely transforms to AML). Considering the known MOA of Luspatercept (works by enhancing late stage erythrocyte maturation) and Imetelstat (kills the malignant clone and abnormal progenitor cells), the former would be expected to improve the need for blood transfusions, hospitalizations, iron overload etc. (a good thing), the latter would be expected to change the course of the entire disease (need for blood transfusions, hospitalizations, iron overload, PFS, overall survival, bone marrow picture, transformation to AML.) And this is why Geron has a booth this year. And after conference presentations. And this is why Dr. Scarlett and Co are smiling. I think Dr. Scarlett suggested we stay tuned, probably not a bad idea. bp

ashah
Posts: 60
Joined: Wed Jan 09, 2019 1:32 pm

Re: Why Dr. Scarlett and Co. are smiling

Post by ashah » Mon Nov 14, 2022 9:42 pm

How I wish I could see and visually assess Dr. Scarlett's confidence (and smile) tomorrow - as they present at Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET

LWS
Posts: 581
Joined: Thu Jul 14, 2016 2:00 am

Re: Why Dr. Scarlett and Co. are smiling

Post by LWS » Tue Nov 15, 2022 4:31 pm

Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET


I would like to get a quick summary of this conference, if possible. Is there any important or new information here?

Bridge to Sell
Posts: 51
Joined: Sat Mar 19, 2022 11:33 pm

Re: Why Dr. Scarlett and Co. are smiling

Post by Bridge to Sell » Tue Nov 15, 2022 6:24 pm

I thought it was encouraging that Scarlett said that TLR would be announced prior to the JP Morgan conference which occurs on January 9th in San Francisco.

Post Reply